Skip to main content
Figure 3 | Genetic Vaccines and Therapy

Figure 3

From: AAV-mediated gene therapy for metabolic diseases: dosage and reapplication studies in the molybdenum cofactor deficiency model

Figure 3

Vector reapplication in adolescence. Liver sections of adult mice after different treatment schemes. Exposure times (exp.) for EGFP are indicated (for further details see figure 1). A) First injection i.v. on day 40 with AAV-MOCS1, second injection intrahepatic with AAV-EGFP after 3 months. B) Only one intrahepatic AAV-EGFP injection 4 months after birth. C) No injection.

Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556